Search

Displaying results 5101 - 5110 of 10000 in total
  1. Drug

    OPC-51803

    go.drugbank.com/drugs/DB05838
    Experimental

    It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence. … It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states.

  2. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS).

  3. Drug

    Elocalcitol

    go.drugbank.com/drugs/DB06194
    Experimental

    Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).

  4. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.

  5. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    Unlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites and a decrease in recrudescence rate. … The combination is an effective and well-tolerated malaria treatment, providing high cure rates even in areas of multi-drug resistance.

  6. Drug

    Afelimomab

    go.drugbank.com/drugs/DB04956
    Experimental

    Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.

  7. Drug

    Velaglucerase alfa

    go.drugbank.com/drugs/DB06720
    Approved

    Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease. … Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase.

  8. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma. … Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP.

  9. Drug

    Vapendavir

    go.drugbank.com/drugs/DB05181
    Investigational

    BTA798 is an antiviral for the treatment of HRV, the common cold virus, known to cause significant clinical complications in sufferers of Asthma and Chronic Obstructive Pulmonary Disease.

  10. Drug

    Phenyl salicylate

    go.drugbank.com/drugs/DB11071
    Approved

    It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in [DB00945] ). … Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes.

    Mixtures: UR N-C Urinary Antiseptic